References
- * of interest
- International Diabetes Federation[Internet]. [ cited 2014 Nov 17]. Available from: http://www.idf.org/diabetesatlas
- International Diabetes Federation[Internet]. [cited 2014 Nov 17]. Available from: http://www.idf.org/sites/default/files/Atlas-poster-2014_EN.pdf
- *Inzucchi S, Buse J, Ferrannini E, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Denotes individualized therapy for patients with type 2 diabetes. Diabetes Care. 2015;38:140–149
- Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–9.
- National Institute for Health and Clinical Excellence. The Management of Type 2 Diabetes, 2015: a patient-centered approach. Diabetes Care. 2015;38:140–149. Denotes individualized therapy for patients with type 2 diabetes.
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ clinical practice guidelines for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2015; 21(1): 1–87.
- Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–2312.
- Schwartz SL, Akinlade B, Klasen S, et al. Safety, pharmacokinetic, and pharmacodynamics profiles of ipragliflozin (ASP 1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13(12):1219–1227.
- Veltkamp SA, Kadokura T, Krauwinkel WJJ, et al. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter inhibitor, on urinary glucose excretation in healthy subjects. Clin Drug Investig. 2011;31(12):839–851.
- Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457–466.
- Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduced calculated renal threshold for glucose excretion and increase urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669–672.
- Kasichayanula S, Liu X, Zhang W, et al. Influence of hepatic impairment on the pharmacokinetics safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011;33:1798–1808.
- Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013;53:601–610.
- Seino Y. Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15(18):2741–2749.
- Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–526.
- Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014;3:1–19.
- Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
- * Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Canagliflozin reduced HbA1c more than glimepiride in patients inadequately controlled on metformin over 52 weeks. Lancet. 2013;13:941–950
- Janssen Research & Development, LLC. The CANTATA-M (CANagliflozin treatment and trial analysis – monotherapy) trial. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[26 Feb 2015]. [cited 2015 Aug 21]. Available from: https://clinicaltrials.gov/ct2/results?term=NCT01081834&Search=Search NCT 01081834.
- Leiter L, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355–364.
- Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care. 2013;36:2508–2515.
- * Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467–477. Improved glycemic control occurred in patients receiving canagliflozin already taking metformin and pioglitazone over 52 weeks.
- Janssen Research & Development, LLC. The CANTATA-MP Trial (CANagliflozin treatment and trial analysis – metformin and pioglitazone). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[26 Feb 2015]. [cited 2015 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01106690?term=nct01106690&rank=1&show_locs=Y#locn. NCT 01106690
- Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 2013;41:72–84.
- Janssen Research & Development, LLC. A safety and efficacy study of canagliflozin in older patients (55 to 80 years of age) with type 2 diabetes. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[26 Feb 2015]. [cited 2015 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01106651?term=01106651&rank=1&show_locs=Y#locn. NCT 01106651
- Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–473.
- Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–2224.
- Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo controlled trial. Lancet. 2010;375(9733):2223–2233.
- * Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–2022.
- Wilding JP, Woo V, Soler NG, et al. Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415.
- Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diab Obes Metab. 2013;15:1154–1160.
- Boehringer Ingelheim. BI 10773 add-on to metformin in patients with type 2 diabetes. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[26 Feb 2015]. [cited 2015 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00749190?term=00749190&rank=1&show_locs=Y#locn. NCT 00749190
- Haring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396–3404.
- Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin. Diabetes Care. 2013;36:4015–4021.
- *Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815–1823 When used with multiple daily injection insulin, empagliflozin improved glycemic control without further hypoglycemia or weight gain, and with reduced insulin requirements.
- Boehringer Ingelheim. Safety and efficacy of BI 10773 as add-on to insulin regimen in patients with type 2 diabetes mellitus. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[26 Feb 2015]. [cited 2015 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01306214?term=01306214&rank=1&show_locs=Y#locn. NCT 01306214.
- Diabetes Care. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes supplementary data. [cited 2015 May 1]. http://care.diabetesjournals.org/content/37/7/1815/suppl/DC1/-/1
- DeFronzo R, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393 In patients inadequately controlled on metformin, empagliflozin plus linagliptin reduced HbA1c further than the individual agents with metformin over 52 weeks.
- Boehringer Ingelheim. Safety and efficacy of empagliflozin (BI 10773)/Linagliptin (BI 1356) fixed dose combination in treatment naïve and metformin treated type 2 diabetes patients. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[26 Feb 2015]. [cited 2015 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01422876?term=01422876&rank=1&show_locs=Y#locn. NCT 01422876.
- Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30(7):1219–1230.
- Seino Y, Sasaki T, Fukatsu A, et al. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30(7):1231–1244.
- Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014;30(7):1245–1255.
- Wilding JPH, Ferrannini E, Fonseca VA, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diab Obes Metab. 2013;15:403–409.
- Astellis Pharma Inc. A study to evaluate the effect of ASP1941 in combination with metformin in adult patients with type 2 diabetes mellitus (BALANCE). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[26 Feb 2015]. [cited 2015 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01117584?term=01117584&rank=1&show_locs=Y#locn. NCT 01117584.
- Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.
- Lapuerta P, Zambrowicz B, Strumph P, et al. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res. 2015;12(2):101–110.
- Merck Sharp & Dohme Corp. MK-8835/PF-04971729 vs. glimepiride in typed 2 diabetes mellitus (T2DM) participants on metformin (MK-8835-002). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Feb 26]. Available from https://clinicaltrials.gov/ct2/show/NCT01999218?term=ertugliflozin&rank=9:NCT01999218
- Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41:445–456.
- Merck Sharp & Dohme Corp. A study of the efficacy and safety of ertugliflozin monotherapy in the treatment of participants with type 2 diabetes mellitus and inadequate glycemic control despite diet and exercise (MK-8835-003). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 26 Feb 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01958671?term=ertugliflozin&rank=8: NCT01958671
- Merck Sharp & Dohme Corp. A study of the efficacy and safety of ertugliflozin in participants with type 2 diabetes mellitus with stage 3 chronic kidney disease who have inadequate glycemic control on antihyperglycemic therapy (MK-8835-001). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01986855?term=ertugliflozin&rank=7: NCT01986855
- Merck Sharp & Dohme Corp. Cardiovascular outcomes following treatment with ertugliflozin in participants with type 2 diabetes mellitus and established vascular disease. In Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01986881?term=ertugliflozin&rank=6: NCT01986881
- Merck Sharp & Dohme Corp. Safety and efficacy of ertugliflozin in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02036515?term=ertugliflozin&rank=5: NCT02036515
- Merck Sharp & Dohme Corp. Efficacy and safety of ertugliflozin (MK-8835/PF-04971729) with sitagliptin in the treatment of participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on diet and exercise (MK-8835-017). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02226003?term=ertugliflozin&rank=4: NCT02226003
- Merck Sharp & Dohme Corp. A study to evaluate the efficacy and safety of ertugliflozin in participants with type 2 diabetes mellitus and inadequate glycemic control on metformin monotherapy (MK-8835-007). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02033889?term=ertugliflozin&rank=3: NCT02033889
- Merck Sharp & Dohme Corp. Ertugliflozin and sitagliptin co-administration factorial study (MK-8835-005). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02099110?term=ertugliflozin&rank=2: NCT02099110
- Merck Sharp & Dohme Corp. Pharmacokinetics, safety, and tolerability of ertugliflozin (MK-8835/PF-04971729) in participants with hepatic impairment and in healthy participants (MK-8835-014). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Feb 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02115347?term=ertugliflozin&rank=1: NCT02115347
- Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee, Dapagliflozin Advisory Committee Meeting [Internet]. Jul 19, 2011. [cited 2013 Dec 16]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/Committees-MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAd-visoryCommittee/UCM262994.pdf#page=1&zoom=auto,0,792
- Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvogaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:479–484.
- Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473–478.
- Boehringer Ingelheim International. 2015. Jardiance: US prescribing information 2013 [Internet]. [cited 2015 Jan 4]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf
- Banerjee SK, McGaffin KR, Pastor-Soler NM, et al. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009; 84(1): 111–118.
- Whalen K, Miller S, St. Onge E. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther. 2015;37(6):1150–1166.
- Zinman B, Inzucchi SE, Lachlin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiov Diabetol. 2014;13:102.
- Neal B, Perkovic V, De Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – A randomized placebo-controlled trial. Am Heart J. 2013;166:217–233e11.
- AstraZeneca. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARETIMI 58).). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Feb 26]. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT01730534?term=TIMI+declare&rank=1. cited 2015 Jan 30.
- Merck Sharp & Dohme Corp. Cardiovascular outcomes following treatment with ertuglizflozin in participants with type 2 diabetes mellitus and established vascular disease (MK-8835-004).). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [ 2015 Feb 26]. [cited 2015 Jan 30]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01986881?term=ertugliflozin&rank=6
- Janssen Pharmaceuticals. 2013. Invokanna: US prescribing information [Internet]. [cited 2014 May 1]. Available from: https://www.invokana.com/prescribing-information.pdf
- Nigro SC, Riche DM, Pheng M, et al. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. Ann Pharmacother. 2013; 47(10): 1301–1311.
- AstraZeneca Pharmaceuticals. 2014. Farxiga: US prescribing information [Internet]. [cited 2014 May 2]. Available from: http://www.azpicentral.com/farxiga/pi_farxiga.pdf#page=1
- Dapagliflozin. In: Lexi-Drugs [Internet]. Hudson (OH): Lexi-Comp, Inc. Updated periodically. [cited 2015 Jan 4]. Available from: http://online.lexi.com.ezproxy.ttuhsc.edu/lco/action/doc/retrieve/docid/patch_f/4927422
- Canagliflozin. In: Lexi-Drugs [Internet]. Hudson (OH): Lexi-Comp, Inc. Updated periodically. [cited 2015 Jan 4]. Available from: http://online.lexi.com.ezproxy.ttuhsc.edu/lco/action/doc/retrieve/docid/patch_f/4230722
- Empagliflozin. In: Lexi-Drugs [Internet]. Hudson (OH): Lexi-Comp, Inc. Updated periodically. [cited 2015 Jan 4]. Available from: http://online.lexi.com.ezproxy.ttuhsc.edu/lco/action/doc/retrieve/docid/patch_f/5279964
- Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev. 2013;29:347–356.
- Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers post prandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;26:2154–2161.
- Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12 week study. Diabetes Obes Metab. 2013;15:1136–1145.
- Goring SM, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2013; 16(5): 433–442.
- Wilding JPH, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124–136.
- Lambers Heerspink HJ, De Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–862.
- Jannsen Prescription Assistance. Invokana® medication website [Internet]. [cited 2015 Jan 4]. Available from: http://www.janssenprescriptionassistance.com/invokana-cost-assistance
- AstraZenica Savings Card. Farxiga™SavingsRx website [Internet]. [cited 2015 Jan 4]. Available from: https://www.activatethecard.com/6800/
- Jardiance® Simple Savings. Jardiance® medication website [Internet]. [cited 2015 Jan 4]. Available from: https://www.jardiance.com
- Janssen Research & Development, LLC. A study of effects of canagliflozin as add-on therapy to insulin in the treatment of participants with type 1 diabetes mellitus (T1DM). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Apr 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT02139943?term=canagliflozin&rank=12
- Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015; 38(3): 412–419.
- Perkins BA, Cherney DZ, Partidge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014; 37(5): 1480–1483.
- Medical University Innsbruck. Dapagliflozin in type 1 diabetes (DapaT1DM). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Apr 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT02211742?term=dapagliflozin±type±1&rank=3
- AstraZeneca. BMS – Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of dapagliflozin in type 1 diabetes. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. [cited 2015 Apr 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT01498185?term=dapagliflozin+type+1&rank=1
- Clinical Trials.gov website [Internet]. [cited 2015 Feb 27]. Available from: https://clinicaltrials.gov/ct2/results?term=SGLT-2&pg=1
- American Diabetes Association. Standards of medical care in diabetes-2015: approaches to glycemic treatment. Diabetes Care. 2015;38(suppl 1):S41–48.
- Vouyiouklis M. Canagliflozin: improving diabetes by making urine sweet. Cleve Clin J Med. 2013;80(11):683–687.
- Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14:539–545.